Overview

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

Status:
Active, not recruiting

Trial end date:
2022-05-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Upadacitinib